UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SP025 Genotype-based combinations of RAS/RAF and PI3K pathway inhibitors

European journal of cancer (1990), 2013-11, Vol.49, p.S7-S7

Banerji, U

2013

Volltextzugriff (PDF)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2020-05, Vol.31 (5), p.619-625

2020

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

British journal of cancer, 2012-09, Vol.107 (7), p.1093-1099

2012

Volltextzugriff (PDF)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Clinical and translational radiation oncology, 2018-08, Vol.12, p.16-20

2018

Volltextzugriff (PDF)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

Annals of oncology, 2015-07, Vol.26 (7), p.1504-1510

2015

Volltextzugriff (PDF)

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Annals of oncology, 2021-02, Vol.32 (2), p.269-278

2021

Volltextzugriff (PDF)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

British journal of cancer, 2009-05, Vol.100 (9), p.1373-1378

2009

Volltextzugriff (PDF)

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

British journal of cancer, 2015-12, Vol.113 (11), p.1541-1547

2015

Volltextzugriff (PDF)

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1918-1925

2018

Volltextzugriff (PDF)

Phase I trial outcomes in older patients with advanced solid tumours

British journal of cancer, 2016-02, Vol.114 (3), p.262-268

2016

Volltextzugriff (PDF)

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

ESMO open, 2024-04, Vol.9 (4), p.102254-102254, Article 102254

2024

Volltextzugriff (PDF)

KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies

Annals of oncology, 2018-10, Vol.29, p.viii1-viii1

2018

Volltextzugriff (PDF)

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Pediatric blood & cancer, 2017-06, Vol.64 (6), p.np-n/a

2017

Volltextzugriff (PDF)

Hsp90 inhibitors in the clinic

Handbook of experimental pharmacology, 2006 (172), p.331

2006

Volltextzugriff (PDF)

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.141-146

2014

Volltextzugriff (PDF)

HSP90 inhibitors in the clinic: what have we learnt?

Annals of oncology, 2015-03, Vol.26, p.ii10

Banerji, U.

2015

Volltextzugriff (PDF)

333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985

European journal of cancer (1990), 2015-09, Vol.51, p.S65-S65

2015

Volltextzugriff (PDF)

Targets, Targets Everywhere but not a Drug to Give

Annals of oncology, 2014-09, Vol.25, p.iv10

Banerji, U.

2014

Volltextzugriff (PDF)

23INTARGETS, TARGETS EVERYWHERE BUT NOT A DRUG TO GIVE

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv10-iv10

Banerji, U.

2014

Volltextzugriff (PDF)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

British journal of cancer, 2012-11, Vol.107 (11), p.1797-1800

2012

Volltextzugriff (PDF)

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-03, Vol.30 (3), p.185-191

2018

Volltextzugriff (PDF)

A phase I II trial of sorafenib and infliximab in advanced renal cell carcinoma

British journal of cancer, 2010-10, Vol.103 (8), p.1149-1153

2010

Volltextzugriff (PDF)

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone

Oncogene, 2000-08, Vol.19 (36), p.4125-4133

2000

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Annals of oncology, 2012-08, Vol.23 (8), p.1968-1973

2012

Volltextzugriff (PDF)

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

European journal of cancer (1990), 2015-09, Vol.51, p.S67-S67

2015

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(179)
Mit Volltextzugriff
(179)

Publikationsform

Artikel
(188)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(41)
Humans
(35)
Oncology
(26)
Biological And Medical Sciences
(22)
Female
(20)
Male
(19)
Medical Sciences
(19)
Physical Sciences
(17)
Middle Aged
(16)
Adult
(14)
Aged
(13)
Cosmic Microwave Background
(13)
Hematology, Oncology And Palliative Medicine
(13)
Animals
(11)
Tumors
(11)
Neoplasms - Drug Therapy
(10)
Technology
(9)
Adolescent
(8)
Astronomy And Astrophysics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

SP025 Genotype-based combinations of RAS/RAF and PI3K pathway inhibitors

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Phase I trial outcomes in older patients with advanced solid tumours

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Hsp90 inhibitors in the clinic

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

HSP90 inhibitors in the clinic: what have we learnt?

333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985

Targets, Targets Everywhere but not a Drug to Give

23INTARGETS, TARGETS EVERYWHERE BUT NOT A DRUG TO GIVE

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit

A phase I II trial of sorafenib and infliximab in advanced renal cell carcinoma

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

Suchergebnisse filtern